Major advances have been made in the development of Alzheimer’s disease (AD) biomarkers in the last two decades, with models of the temporal evolution of AD biomarkers offering the possibility of staging the course of the disease. Despite the achievements in this field, a major unmet need is the standardization of quantitative metrics for AD imaging biomarkers, according to an article published in the May issue of Radiology.
Immunotherapy with the antibody bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD) resulted in decreases in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process, according to Phase II research published online April 2 in the Archives of Neurology.
Florbetapir F18 is an effective biomarker for Alzheimer’s disease (AD) pathology and has a wide effective dose range and high test—retest reliability, according to a study published in the March 1 issue of the Journal of Nuclear Medicine.
A new magnetic resonance spectroscopy (MRS) technique may offer a method to detect and track a protein associated with a genetic mutation in brain tumor cancer cells. The method could inform diagnosis of glioma and provide prognostic information, according to a study published online Jan. 26 in Nature Medicine.
The CHEST Foundation has awarded a Roswell Park Cancer Institute research team a $100,000 grant to develop a blood test to help diagnose lung cancer in patients before they undergo a biopsy.
Carestream Molecular Imaging is sponsoring a complimentary seminar on Imaging Technologies & Strategies in Pre-Clinical Small Animal Research on Dec. 6, in Cambridge, Mass.
Boston University School of Medicine has received a $13.6 million grant to be the lead institution in a study aimed at developing technologies for the early detection of lung cancer. The five-year multi-site, multi-phase study that will focus on active military personnel and veterans is funded by the U. S. Department of Defense Lung Cancer Research Program.
Compared with changes in biomarkers, changes in cognitive abilities appear to be stronger predictors of whether an individual with mild cognitive impairment (MCI) will develop Alzheimer’s disease, based on research published in the September issue of Archives of General Psychiatry.
Imaging blood perfusion in pig livers; A molecular theranostics primer; Mice provide a biomarker roadmap for human approach; Simultaneous PET/3D FOT is feasible
Researchers continue to make headway in grasping the biological nature of Alzheimer’s disease, with a recent study discovering significant increases in the beta-amyloid uptake of florbetapir F18 as viewed on PET, published July 11 in the Archives of Neurology.
Researchers at Fred Hutchinson Cancer Research Center in Seattle have demonstrated in mice that the performance of a novel biomarker-development pipeline using targeted mass spectrometry is robust enough to support the use of an analogous approach in humans, based on findings by principal investigator Amanda Paulovich, MD, PhD, an associate member of the Hutchinson Center's clinical research division, and colleagues published in Nature Biotechnology.
Cardinal Health has opened its first cyclotron facility in the state of Georgia, expanding its capability to manufacture molecular imaging biomarkers that aid in the early diagnosis, monitoring and treatment of cancer, neurological disorders and heart disease.
|
|
|
|
RSS 
